NOVEL NANOPARTICLES FOR THE ORAL DELIVERY OF LOW MOLECULAR WEIGHT HEPARIN: IN VITRO AND IN VIVO ASSESSMENT

  • Nallaguntla Lavanya Sri padmavati mahila vishwavidhyalayam, Womens university, Tirupati
  • Indira Muzib sri Padmavati Mahila Vishwavidhyalayam Womens university Tirupathi
  • Aukunuru Jithan Aizant Drug Solutions Pvt. Ltd., Hyderabad.
  • Balekari Umamahesh faculty of pharmacy, University College of Pharmaceutical Sciences, Kakatiya University, Warangal.

Abstract

Objective: The objective of the present study was to prepare and evaluate a novel oral formulation of nanoparticles for the systemic delivery of low molecular weight heparin (LMWH).

 Methods: Nanoparticles were prepared by polyelectrolyte complexation (PEC) method using polymers sodium alginate and chitosan. Entrapment efficiency of LMWH in nanoparticles was found to be  ̴88%. Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X‑ray diffraction (XRD), Scanning electron microscopy (SEM)  studies carried for nanoparticles. In vitro release studies were performed for the formulations. Ex vivo permeation studies were performed optimized formulation by using small intestine of rat and in vivo studies were conducted on rat model.

Results: In vitro release studies demonstrated that the release of LMWH was negligible in the stomach and high in the small intestine. FTIR has indicated that there is no interaction between the ingredients in nanoparticle. DSC and XRD studies confirmed that the amino groups of chitosan interacted with the carboxylic groups of alginate. Invitro % drug release of 95% was shown by formulation AC5. Ex vivo permeation studies have elucidated that Ì´ 73% of LMWH was transported across the epithelium. Nanoparticles have shown enhanced oral bioavailability of LMWH as revealed by 4.5 fold increase in AUC of plasma drug concentration time curve.

Conclusion: The results suggest that the nanoparticles prepared can result in targeted delivery of LMWH into systemic circulation via intestinal and colon routes. Novel nanoparticles thus prepared in this study can be considered as a promising delivery system.

Keywords: Antifactor Xa activity, Chitosan, Differential scanning calorimetry, Sodium alginate, Low-molecular-weight heparin, Oral bioavailability.

Author Biographies

Nallaguntla Lavanya, Sri padmavati mahila vishwavidhyalayam, Womens university, Tirupati
pharmaceutics
Indira Muzib, sri Padmavati Mahila Vishwavidhyalayam Womens university Tirupathi
pharmaceutics
Aukunuru Jithan, Aizant Drug Solutions Pvt. Ltd., Hyderabad.
pharmaceutics

References

1. Andersson M, Löfroth JE. Small particles of a heparin/chitosan complex prepared from a pharmaceutically acceptable microemulsion. Int J Pharm 2003;257(1-2):305-9.
2. Wang J, Tan H, Yu A, Ling P, Lou H, Zhai G, et al. Preparation of chitosan-based nanoparticles for delivery of low molecular weight heparin. J Biomed Nanotechnol 2011;7(5):696-703.
3. Aysu Y, Ferhan S. An overview of modified release chitosan, alginate and Eudragit RS microparticles. J Chem Pharm Res 2010;2(3):704-21.
4. Scala-Bertola J, Gajdziok J, Rabisková M, Bonneaux F, Lecompte T, Sapin A, et al. Pellets for oral administration of low-molecular-weight heparin. Drug Dev Ind Pharm 2009;35(12):1503-10.
5. Kim SK, Vaishali B, Lee E, Lee S, Lee YK, Kumar TS, et al. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb Res 2006;117(4):419-27.
6. Lin IC, Liang M, Liu TY, Monteiro MJ, Toth I. Cellular transport pathways of polymer coated gold nanoparticles. Nanomedicine
2012;8(1):8-11.
7. Jogala S, Rachamalla SS, Aukunuru J. Development of subcutaneous sustained release nanoparticles encapsulating low molecular weight heparin. J Adv Pharm Technol Res 2015;6(2):58-64.
8. Yang T, Nyiawung D, Silber A, Hao J, Lai L, Bai S. Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight heparin. AAPS PharmSciTech
2012;13(4):1309-18.
9. Bigucci F, Luppi B, Cerchiara T, Sorrenti M, Bettinetti G, Rodriguez L, et al. Chitosan/pectin polyelectrolyte complexes: Selection of suitable preparative conditions for colon-specific delivery of vancomycin. Eur J Pharm Sci 2008;35(5):435-41.
10. Saether HV, Holme HK, Maurstad G, Smidsrod O, Stokke BT.
Polyelectrolyte complex formation using alginate and chitosan. Carbohydr Polym 2008;74:813-21.
11. Liao IC, Wan AC, Yim EK, Leong KW. Controlled release from fibers of polyelectrolyte complexes. J Control Release 2005;104:347-58.
12. Hamman JH. Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems. Mar Drugs 2010;8:1305-22.
13. Cheung RC, Ng TB, Wong JH, Chan WY. Chitosan: An update on potential biomedical and pharmaceutical applications. Mar Drugs
2015;13(8):5156-86.
14. Li X, Xie H, Lin J, Xie W, Maa X. Characterization and biodegradation of chitosan–alginate polyelectrolyte complexes. Polym Degrad Stabil 2009;94:1-6.
15. Han T, New N, Furuike T, Tokura S, Tamura H. Methods of N-acetylated chitosan scaffolds and it’s in vitro biodegradation by lysozyme. J Biomed Sci Eng 2012;5:15-23.
16. Aiba S. Studies on chitosan: 4. Lysozymic hydrolysis of partially N-acetylated chitosans. Int J Biol Macromol 1992;14(4):225-8.17. Hoffart V, Ubrich B, Simonin C, Babak V, Vigneron C, Hoffman M, et al. Low molecular weight heparin-loaded polymeric nanoparticles: Formulation characterization and release characteristics. Drug Dev Ind Pharm 2002;28(9):1091-9.
18. Bagre AP, Jain K, Jain NK. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: In vitro and in vivo assessment. Int J Pharm 2013;456(1):31-40.
19. Paliwal R, Paliwal SR, Agrawal GP, Vyas SP. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation. Int J Pharm 2012;422(1-2):179-84.
20. Deepak SN, Veda Hari BN. Optimization, development and evaluation of microemulsion for the release of combination of guaifenesin and phenylephrine. J Appl Pharm Sci 2013;3(9):48-56.
21. Ganeshkumar M, Ponrasu T, Sathishkumar M, Suguna L. Preparation of amphiphilic hollow carbon nanosphere loaded insulin for oral delivery. Colloids Surf B Biointerfaces 2013;103:238-43.
22. García-Manzano A, González-Llaven J, Lemini C, Rubio-Póo C.
Standardization of rat blood clotting tests with reagents used for humans. Proc West Pharmacol Soc 2001;44:153-5.
23. Lemini C, Rubio-Póo C, Silva G, García-Mondragón J, Zavala E, Mendoza-Patiño N, et al. Anticoagulant and estrogenic effects of
two new 17 beta-aminoestrogens, butolame [17 beta-(4-hydroxy-
1-butylamino)-1,3,5(10)-estratrien-3-ol] and pentolame [17 beta- (5-hydroxy-1-pentylamino)-1,3,5(10)-estratrien-3-ol]. Steroids
1993;58:457-61.
24. Rafie A, Alimohammadian MH, Gazori T, Riazi-rad F, Fatemi SM, Parizadeh A, et al. Comparison of chitosan, alginate and chitosan/ alginate nanoparticles with respect to their size, stability, toxicity and transfection. Asian Pac J Trop Dis 2014;4(5):372-7.
25. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D.
Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 2007;24(12):2198-206.
26. Ilango KB, Kavimani S. A systematic review of mathematical models of pharmaceutical dosage forms. Int J Curr Pharm Rev Res
2015;6(1):59-70.
27. Mukhopadhyay P, Chakraborty S, Bhattacharya S, Mishra R, Kundu PP. pH-sensitive chitosan/alginate core-shell nanoparticles for efficient and safe oral insulin delivery. Int J Biol Macromol 2015;72:640-8.
28. Sonaje K, Lin YH, Juang JH, Wey SP, Chen CT, Sung HW. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009;30(12):2329-39.
Statistics
267 Views | 363 Downloads
How to Cite
Lavanya, N., I. Muzib, A. Jithan, and B. Umamahesh. “NOVEL NANOPARTICLES FOR THE ORAL DELIVERY OF LOW MOLECULAR WEIGHT HEPARIN: IN VITRO AND IN VIVO ASSESSMENT”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 2, Feb. 2017, pp. 254-61, doi:10.22159/ajpcr.2017.v10i2.15514.
Section
Original Article(s)